Experimental group:Adebrelimab

4 trials

Sponsors

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University Affiliated Cancer Hospital, Affiliated Hospital of Jiangnan University, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Conditions

Biliary malignant tumor, BTCSolid tumorsThymic carcinomahepatocellular carcinoma, HCC

Phase 2

Adebrelimab combined with apatinib and platinum-based chemotherapy for neoadjuvant treatment of potentially resectable thymic carcinoma: A single-center, single-arm, phase II clinical study

Active, not recruitingChiCTR2600121533

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)Thymic carcinoma

Start: 2026-04-01Updated: 2026-04-14

Phase 4

Adebrelimab (PD-L1) combined with gemcitabine and cisplatin (GP regimen) for unresectable advanced biliary tract cancer

Active, not recruitingChiCTR2400087017

Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityBiliary malignant tumor, BTC

Start: 2024-07-18Updated: 2024-07-22

Exploratory study on the combination of Adebrelimab and Apatinib in the treatment of PD-1 inhibitor induced liver cancer

Active, not recruitingChiCTR2400087077

Shandong First Medical University Affiliated Cancer Hospitalhepatocellular carcinoma, HCC

Start: 2024-07-31Updated: 2024-07-22

Unknown Phase

Adebrelimab resumption after irAEs in solid tumors: a real-world study

Active, not recruitingChiCTR2500101774

Affiliated Hospital of Jiangnan UniversitySolid tumors

Start: 2025-05-01Updated: 2025-05-05

Related Papers

Real-world study of adebrelimab for immune resumption after immune-related adverse events (irAEs).

Journal of Clinical Oncology2026-05-28